Agent for treating septic wounds, pus pockets and trophic ulcers

FIELD: medicine.

SUBSTANCE: invention represents an agent for treating septic wounds, pus pockets and trophic ulcers containing betaine hydrochloride, methyluracil, trimecaine, pepsin powder and polyethylene oxide 400 with the ingredients taken in certain proportions, wt %, and polyethylene oxide 400 is taken in an amount of 87.0-84.0 ml.

EFFECT: invention provides fastening necrolysis, intensifies bactericidal action, stimulates regeneration, prevents secondary infection.

4 ex

 

The invention relates to the field of medicine, namely to medicines used for the local treatment of infected purulent wounds of different localization and etiology in the first (necrotic), in the second and partially the third phases of wound healing, infected burns II-IV degree, trophic ulcers and nonhealing wounds festering, festering residual cavity of liver and other organs, prevention of infectious-inflammatory complications after hydatidectomy, postoperative and post-traumatic wounds and fistulas, wounds once opened purulent-inflammatory diseases of the skin and subcutaneous tissue, pressure ulcers, etc.

According to the literature in medical practice knows lots of different drugs used in the form of medicines, suspensions and ointment form with microlithiasis, bactericidal, analgesic, draining, cytoprotective, buffer and stimulating regeneration the action used for the treatment of various inflammatory processes.

All known drugs differ in chemical structure, mechanism of action and pharmacological activity.

Widespread at the moment medicines in the form of solutions, suspensions and ointments, main ingredients, which procedimenti way.

Analogs of the invention

Known following tools and materials:

1) a means for the dissolution of necrotic tissue following composition: pepsin 5,0-10,0; ascorbic acid 1,0-5,0; lactic acid (96%) 1,0-3,0; urea 10,0-25,0; water 10,0-16,0; hydrophobic base (lanolin anhydrous + lard in the ratio 3:1) - 100.0; AC No. 439288 issued 15.08.74, class A61K 9/06 (Leontiev-Tokina A. A.);

2) a drug for the treatment of purulent wounds and trophic ulcers according to the following recipe: pepsin - 15,0; ascorbic acid - 30,0; glucose - 54,25; the peroxide - 0,75; AC No. 1149977 issued 15.04.85, class A61K 37/57 (Kaplan V. A. and feigelman S. S.);

3) suspension for the treatment of trophic ulcers and nonhealing wounds festering on the following recipe: pepsin - 4,0; ascorbic acid - 1,0; the peroxide is 0.1; methyluracil - 4,0; polyglukin - to 50.0 ml; patent No. 2160135 issued 10.12.2000, class A61N 5/06, A61K 38/43 (Magomedov M. G., Khamidov, A. I., M. R. Ramazanov, duginov A. A.);

4) levosin - ointment at 100,0 g, which contains chloramphenicol 1.0 g, sulfadimetoksin and methyluracil, 4.0 g, trimecaine 3.0 g, polyethylene oxide 88,0 g, has antimicrobial, local anesthetic, anti-inflammatory and stimulating the regeneration of the action, used for the treatment of purulent wounds of different etiology. Moszkowski, M. D. "drugs". - 15th ed., Rev., Rev. and extra - M., 2007. - S. 815;

5) levomekol ointment, 100,0 g whe� contains chloramphenicol 0.75 g, of methyluracil, 4.0 g of polyethylene glycol 95,25 g, has antimicrobial, anti-inflammatory effect. Used for the treatment of purulent wounds. Moszkowski, M. D. "drugs". - 15th ed., Rev., Rev. and extra - M., 2007. - S. 815;

Criticism analogues

The disadvantages of the above medicines should be recognized:

1. Many chemical antiseptic preparations and antibacterial agents used for the treatment of purulent wounds and najnovsia residual cavities of the bodies of purulent-septic complications, have side effects and are often not recommended to use due to the possible worsening of developing degenerative, metabolic disorders in the tissues - disreguarding processes.

2. Not effective enough, because the medicines used, in which separate their application won certain positions in purulent surgery, and separately has a weak necroticism, anti-inflammatory, local anesthetic and antiseptic properties.

3. Some medicines are not enough creates the optimum pH for pepsin due to the use of weak organic acids, insufficient antibacterial and nekroliticescoe activity of the applied compositions.

4. Used drug activity Firmin�s limited in time because of the rapid alkalinization of wound, due to the lack of buffer additives, stabilizing pH in the wound.

5. In many cases, do not apply substances that can exert a cytoprotective effect on regenerating tissue, which is an active stimulant of regenerative processes.

6. In these ways underused possibility of direct feed plastic material to regenerating tissues.

7. May experience hypersensitivity to funds in the form of allergic reactions and other side effects.

8. The solutions and ointments are restricted because their activity is manifested in different ways in relation to certain diseases.

9. In their application marked dermatitis, skin rash, itching and irritation of the skin around the wound.

10. Suppresses the local immune system some drugs that are included in the composition of the suspensions and ointments.

11. The significant cost of modern antibacterial agents, proteolytic enzymes, requiring for this pathology high material costs.

The prototype of the invention

As the closest prototype of the proposed invention is a combination tool Necrotization" for the treatment of trophic ulcers and nonhealing wounds festering, patent RU No. 2278689 issued 10.12.2004, class A61P 17/02, A61K 38/48, A61K 38/39, A61K 38/17 (Emirs G. N.).

Cu�teak prototype

The essence of the prototype.

The tool Necrotization" contains (g/100 ml solution): methyluracil - 0,9-1,1; pepsin - 3,6-4,4; betaine hydrochloride - 3,6-4,4; sodium chloride 9,0-11,0; distilled water - 100.0; has necroticism, antibacterial, drainage, buffer and stimulating the regeneration effect. Used for the treatment of purulent wounds and trophic ulcers.

However, in the course of treatment noted the following disadvantages:

- the tool has quite a pronounced therapeutic effect;

- possible local irritating effect expressed in the reddening of the skin or lung irritation, a burning sensation;

- not effective enough, because it has weak anti-inflammatory, local anesthetic and drainage of the property;

- cannot fully provide everything necessary for the regeneration conditions, such as: balanced moist environment, activation of angiogenesis, the ability to accelerate the formation of collagen fibers, granulation and cell migration of the epithelium;

- not sufficiently effective in removing excess exudate, maintain humidity and provide gas exchange.

The purpose of the invention

The aim of the invention is to provide a simple, affordable, cheap and efficient medications with a wide range of applications. However, he should be deprived of negative�positive side effects, but the application should not have contraindications should be accessible and easy to use.

Summary of the invention

The essence of the invention consists in that as components of drugs used (g/100 ml solution): pepsin - 4,0-4,5; betaine hydrochloride - 4,0-4,5; methyluracil - 3,0-4,0; trimekain 2,0-3,0; polyethylene oxide-400 87,0-84,0 ml.

The technical problem solved by the proposed medicinal product is to ensure effective treatment of purulent wounds, trophic ulcers, festering residual cavities of the bodies of purulent-septic complications, etc.

The technical result obtained by implementing the proposed drug in the treatment of purulent wounds, trophic ulcers, festering residual cavities of the bodies of purulent-septic complications, is provided by accelerating necrolysis, enhance bactericidal effects, stimulation of regeneration, delivery required for anabolic processes nutrients directly to the regenerating tissues, protect regenerating tissue from local pain and external influences, ensuring the prevention of secondary infection.

The achievement of specified technical result consists in the local application in the first phase of wound process the newly proposed media�TWA, conditionally named "Beltram", with the following ratio (g/100 ml solution): pepsin - 4,0-4,5; betaine hydrochloride - 4,0-4,5; methyluracil - 3,0-4,0; trimekain 2,0-3,0; polyethylene oxide-400 87,0-84,0 ml.

Method of application of the proposed tools

After standard processing of wounds and burns the drug is applied directly on the wound surface in a thin layer (after that impose a sterile gauze bandage) or a gauze bandage with subsequent application to the lesion. Tampons saturated with, loosely fill the cavity of purulent wounds after debridement, gauze turunda tool is introduced into tracts. If there festering residual cavity through the drainage tube is introduced into the cavity means commensurate with the size of the cavity. In the treatment of infected burns tool used daily or 2-3 times a week depending on the amount of purulent discharge. The second and partially the third phase of wound process this composition on a gauze bandage is used in conjunction with drugs of collagen (mostly - chopped medical catgut).

The most effective ratio of the medicinal component in the composition "Beltram" was identified by experimental studies and by numerous clinical observations.

In�e are included in the product components are allowed to use MOH. Moszkowski, M. D. "drugs". - 15th ed., Rev., Rev. and extra - M., 2007. - 1206 S.

The ingredients of the present composition when dissolved not come between them in chemical relations, as proven by a spectrophotometric method.

Pepsin is a gastric enzyme with the highest proteolytic activity of all other enzymes in the body.

This enzyme belongs to one of the largest groups of enzymes - proteolytic enzymes (proteases). They belong to the class of hydrolases, subclass of peptideatlas and catalyze the cleavage of proteins and polypeptides. Pepsin hydrolyzes peptide bonds and cleaves almost all natural proteins.

As an ingredient of the present composition was used the most accessible and cheap pork pepsin - abomin. In the literature, the authors have not found data about the possibility of an overdose of pepsin.

Betaine (N-trimethylglycine, Okinawan, Licinius, betafin) is a natural nitrogenous lipotropic substance of vegetable origin, a derivative of the natural amino acid glycine. It is a readily water-soluble powder. The molecular formula of betaine With5N11NO2chemical formula - (CH3)3N+-CH2COO-(preparation amphotere).

In the molecule of betaine are active m�the other group (CH 3-), which are necessary for normal metabolism. Attaching a methyl group (methylation) is a mandatory stage of the most important biochemical reactions.

The human body cannot synthesize methyl group, and remove them from food. Due to its direct involvement in methylation reactions betaine has a great influence, in particular, on lipid metabolism, with a lipotropic effect, as its composition is close to the choline and lecithin. Betaine is involved in the metabolism of methionine.

In addition, betaine performs the function of osmoprotective, i.e. helps to maintain water balance in cells, tissues, and reduces platelet aggregation.

Betaine is used in pharmacology for the treatment of liver disease, alcohol treatment in toxic poisoning, in the form of food additives in the composition nutritition drugs.

Betaine hydrochloride (or hydrochloride) is chemically 1-carboxy-N,N,N-trime-thylmethanaminium chloride. Clean 5% solution of betaine hydrochloride has a pH of 1.

Betaine hydrochloride dissociates in solution to the free betaine and diluted hydrochloric acid with a pH of 2-2. 5, used in tablet formulation "acidin-pepsin" for oral administration for the treatment gipacidnyh gastritis in combination with pepsin.

In the literature no data are known about the possibility of an overdose of betaine � betaine hydrochloride.

Meteorical (2,4-dioxo-6-methyl-1,2,3,4-tetrahydropyrimidin). White crystalline powder, odorless, slightly soluble in water (up to 0.9% at 20°C) and alcohol. On chemical structure methyluracil refers to a derivative of pyrimidine. According to experimental data, a number of drugs in this group (methyluracil, pentoksil etc.) has anabolic and anti-catabolic activity. These drugs accelerate the process of cell regeneration, accelerate wound healing, stimulate cellular and humoral defense factors. They has anti-inflammatory effects.

Trimekain is white or white with a faint yellowish tinge crystalline powder. Very easily soluble in water, in alcohol. He is an active local anesthetics. Low toxicity. Does not contain para-aminobenzoic acid, and therefore is not valid antisurveillance.

Polyethylene oxide-400 - 30% solution for local treatment of purulent wounds due to the high osmotic activity, has a strong dehydrating (drying) action, easily penetrates into the tissues, conveying related drugs included in the combined funds. Due to high hydration activity of the composition in a short time (2-3 days) usually provides the elimination of perifocal edema� and wound cleansing from necrotic content. When the local wound on the surface exert a bacteriostatic effect, accelerates the cleansing and healing of wounds. Applied externally, a solution of polyethylene oxide-400 has no obscherezorbtivnymi toxic or local irritating action.

To use the "Beltram" in clinical practice in the second and partly third phases of wound healing composition is added to the collagen preparations.

Collagen is the most abundant protein in the human body. It is easy to lyse tissue and bacterial proteases slow release contained drugs. Decomposing on the wound surface into simpler compounds, collagen metabolites are actively involved in metabolism at the cellular level and stimulates reparative processes, and in the purulent cavity is introduced into the liquid collagen containing hydrolyzed collagen (gelatin). Collagen contains large amounts of glycine (33%) and Proline (10%) - two amino acids that are the basic components of the molecules of collagen and elastin fibers that form connective tissue organs in the human body. Collagen and collagenopathies materials have no toxic, irritating, antigenic, carcinogenic action.

The technique of treatment by this method.

For nepo�direct treatment means Beltram" is prepared ex tempore by mixing batches of ingredients in the flask followed by the addition of polyethylene oxide-400 - 30% solution in normal conditions, and does not require sterilization, as it has expressed itself bactericidal activity.

According to the proposed method in the 1st phase of wound process in the first 3-5 days after a proper toilet of the wound surface or after washing purulent cavity preservative under aseptic conditions imposed 3-4 ply gauze, heavily soaked in Beltram" or tool is introduced into the cavity in the amount of 2/3 of the volume of wash antiseptic solution in a preferred embodiment: pepsin 4,0; betaine hydrochloride 4.0; methyluracil 3.0; trimecaine 3.0 g; polyethylene oxide-400 86,0 (pH of 2.0). The frequency of changing dressings or introduction to purulent cavity means is carried out 1 time per day.

Subsequently, after purification of the festering wounds or purulent cavities from necrotic discharge, in aseptic conditions at its surface covered with chopped collagen (catgut) or other officinal collagen-containing dressings with a layer thickness of 3 mm or in the cavity is introduced into the liquid collagen Liquid. Collagen layer overlaps the first layer of gauze bandage (cut according to the contours of the wound surface) of 3-4 layers, liberally soaked in Beltram". On top of napkins Annularly many superimposed perforated microirrigation, covered another -4 ply dry sterile cloth.

Through microirrigation in a bandage with a frequency of 1-2 times a day a small quantity of "Beltram" diluted in a ratio of 1:2, and purulent cavity before the introduction of Beltram" in the amount of 2/3 the volume of the residual cavity with preliminary addition of liquid collagen Liquid, washed with normal antiseptic solution through the drainage tube with microirrigation and their subsequent closure within 2 hours. Change dressings made with an interval of 4-5 days.

If trophic ulcer or suppurative wound is healing without the use of autodermoplasty, regular transparent after soaking layers of bandages in 3% hydrogen peroxide if necessary, you can add on its surface cut into small pieces under aseptic conditions collagen (catgut) or other offitsialnye collagen-containing dressings, not completely removing remaining on the surface of the granulation tissue collagen film.

In the treatment of infected burns tool used daily or 2-3 times a week depending on the amount of purulent discharge.

The tool Beltram" is an effective combination drug for the topical treatment of many diseases: infected and purulent wounds of different localization and etiology in all phases of wound healing, infected burns of II-IV degree�Yeni, trophic ulcers and nonhealing wounds festering, festering residual cavity of liver and other organs, prevention of infectious-inflammatory complications after hydatidectomy, postoperative and post-traumatic wounds and fistulas, wounds once opened purulent-inflammatory diseases of the skin and subcutaneous tissue, bedsores, etc., requiring the removal of pain, inflammatory reaction and regeneration stimulator. The effectiveness of the product is ensured by choice of the components of its active part, and their quantity.

The treatment time in comparison with known drugs are drastically reduced and are only on average 15 days for a course. Thus there are no side effects, therefore it has expanded the patient population and patients.

When using this tool, there is a pronounced improvement of the General and local clinical status.

The tool can be used both for treatment and prophylaxis of purulent-inflammatory response to injury.

The proposed remedy "Beltram" has passed approbation in polyclinic №6, Makhachkala, Department of surgery veterans RMC MOH RD, the burns unit at RCH MOH RD.

Clinical study of the drug carried out on 45 patients. With all the positive indications therapeutic use�quarter action. Negative side effects were not observed in any of the cases.

The technical result is achieved by the combined use of the components included in the tool Beltram", which together allowed us to obtain a therapeutic agent that has necroticism, bactericidal, analgesic, draining, cytoprotective, buffer and stimulating regeneration the action behind its extensive use in the treatment of many diseases. The authors found that the tool Beltram" contains the components in amounts which provide at their joint application of the most pronounced therapeutic effect, and used liquid Foundation contributes to the effective maintenance of an optimal environment for good wound healing.

Unlike the proposed funds from the prototype is that the product contains components known in the pharmacology of medications used in routine medical practice. As components of drugs used of polyethylene oxide-400 - 30% solution, powder of pepsin, betaine hydrochloride, methyluracil, trimecaine and when combined with their use in the proposed combination are due to the synergy of their actions is pronounced clinical effect, which dramatically reduces the time laciniata comparison with known drugs for local treatment.

An example of a specific implementation method

The remedy proposed in the invention, used in the treatment of infected and purulent wounds of different localization and etiology, infected burns II-IV degree, trophic ulcers and nonhealing festering wounds, festering residual cavity of liver and other organs, and post-traumatic wounds and fistulas, wounds once opened purulent-inflammatory diseases of the skin and subcutaneous tissue, etc., 45 patients in the surgical Department of the hospital of the veterans RMC MOH RD, the burns unit at RCH MOH RD, doctor's surgery polyclinic №6 Makhachkala. With all the indications noted a positive therapeutic effect. Negative side effects were not observed in any of the cases.

Example 1. Patient K., 72 years old, appealed with extensive purulent wound on the right foot to the lower leg area in the surgical Department of the hospital of the veterans RMC MOH RD. During the week after the patient toilet wound with 3% hydrogen peroxide solution was applied to a gauze pad utility Beltram" adopted in the clinic the methodology. The dressing was changed once in 5 days, in a subsequent ligation was performed after wound toilet 1.5% hydrogen peroxide solution on day 6. Ligation was performed without pain patient. After 12 days the wound healed. Bo�the diesel was discharged to outpatient treatment. When re-examination within a month the wound healed completely tender scar.

Example 2. Patient B., age 59, went to the hospital with nonhealing wounds in the lower third of both legs after a car accident. Duration of existence of the wound 12 months. Before treatment the patient was treated in the clinic by place of residence. On examination, the patient found that in the lower third of the left Shin there is a wound area of 82 cm2. On the right tibia in the lower third there is a wound measuring 30 cm2. The bottom of the ulcer is covered with necrotic films, saped edges of the wound and hyperemic. Bacteriological examination of discharge from the wound detected Staphylococcus aureus, sensitive to Cefotaxime, ampioks. The patient after using the toilet wounds imposed gauze utility Beltram" according to the clinic's methodology for 10 days. On the 11th day according to the planimetry of the area of the wound on the right leg was 13 cm2and the left - 41 cm2. The patient was discharged to outpatient treatment. Complete wound healing on follow-up data occurred on the 24th day.

Example 3. Patient M., 62 years old, was admitted to hospital for planned treatment for nonhealing wounds in the right lower limb on the background of varicose veins of the lower extremities. Duration of existence of the ulcer - 8 years. Before applying netnoc�atna treated on an outpatient basis. During examination of the patient revealed that in the lower third of the right tibia is ulcer measuring 26 cm2with profuse purulent discharge; the bottom of the ulcer is filled with sluggish granulations, covered with necrotic films, saped edges of the wound, the skin around with symptoms of hyperpigmentation.

The patient was treated for the claimed drug. On the 10th day of treatment the wound size was 13 cm2on the 20th day there was almost complete healing of the wounds.

Example 4. Patient T., age 69, was admitted to the hospital with a diagnosis of venous trophic ulcer in the lower third of the right tibia on the anteromedial surface size 62 cm2, hyperpigmentation in the lower third of the right tibia. Conducted local treatment tool Beltram" during the week. Sick after going to the toilet of the wound with 3% hydrogen peroxide solution was putting a napkin utility Beltram" adopted in the clinic the methodology and conducted the external elastic compression. The dressing was changed once a week. In subsequent ligation performed after wound toilet 1.5% hydrogen peroxide solution in 4 days. Ligation was performed without pain. 12 days trophic ulcer healed. The patient was discharged to outpatient treatment on day 18 with almost completely sagusa ulcer. When re-examination within 6 months of trophic ulcer healed completely ninimum.

Thus, as shown by the treatment, the tool Beltram" has local anti-inflammatory action, promotes the resorption of inflammatory process, exhibits analgesic and wound healing effect that, with the ease of use and the absence of side effects makes extensive use of the drug in outpatient and inpatient settings.

The features of the invention, distinct from the prototype

1. The tool Beltram" has quite a pronounced therapeutic effect.

2. There is no local irritating effect on the wound.

3. The drug has a pronounced anti-inflammatory, local anesthetic, antiseptic and wound-healing effect.

4. When using the proposed combination of drugs provides everything you need for the regeneration conditions (balanced moist environment, activation of angiogenesis, speeds up the formation of collagen fibers, granulation and cell migration of the epithelium).

5. Promotes lymphatic drainage of tissues (it is proved that the acidification of tissues of 7.35 to 5.9 increases its volume exudation by 20% due to the flow of the lymph, while 30% solution of polyethylene oxide-400 in the mixture stimulates the flow of tissue fluid with toxic elements and microflora in the dressing).

The positive effect of trimarine of the invention

The effectiveness is confirmed by numerous clinical observations.

The proposed product unlike any other currently known drugs can improve the results of treatment of patients with purulent wounds of different localization and etiology in all phases of wound healing, infected burns of II-IV degree, trophic ulcers and nonhealing purulent wounds, festering residual cavities of the liver and other organs, and post-traumatic wounds and fistulas, etc.

The results obtained from the use of this tool can accelerate at 1.5-2 times the wound cleansing from necrotic process; to ensure the rapid elimination of pathogenic microflora due to the bactericidal action of the drug; to intensify the processes of wound healing by stimulating regeneration raznodejstvujushchih agents and to provide optimal conditions for the mechanism of wound contraction due to the ingredients included in the preparation. The advantage of the proposed means of bacteriologically confirmed, cytomorphological, clinically.

The combined use of the components of the compositions and preparations of collagen in this way leads to a pronounced synergistic effects on the healing of purulent wounds.

Given the low cost of the ingredients used�used as part of funds you can expect a significant economic efficiency from introduction into clinical practice.

Sources of information

Emirs G. N. Kombinirovannogo means "Necrotization" for the treatment of trophic ulcers and nonhealing wounds festering. Patent RU №2278689 issued 10.12.2004, class A61P 17/02, A61K 38/48, A61K 38/39, A61K 38/17 - prototype.

Drug for treatment of purulent wounds, purulent cavities and ulcers containing antiseptic preparations and liquid base, characterized in that it consists of drugs in the following ratio, wt. %:

betaine hydrochloride4.0 to 4.5
methyluracil3,0-4,0
trimekain2,0-3,0
powder of pepsin4.0 to 4.5
liquid Foundation polyethylene oxide-40087,0-84,0 ml



 

Same patents:

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to dermatology and surgery, and can be used for skin regeneration, repair and grafting. That is ensured by using an absorbable multilayer structure. That is preceded by preparing (adapting) this structure by exposing to an UV lamp at an emitting power of 10-20 W at 15-45 cm from a collagen sponge surface of the membrane for 2-4 hours. Alternatively, the adaptation procedure is developed by cross-linking with dehydration and thermal treatment in the vacuum medium at a pressure <200 mbar and 100°C for 24 hours or with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) in a water solution containing approximately 0.1-0.6 g of EDC in approximately 0.3-2 g of the collagen sponge matrix. Cross-linking agents, such as hyaluronan, hexethylene diisocyamate, N-hydroxysuccinimide (NHS) or hyoxal are used. The above absorbable multilayer structure comprises a barrier laminate of a purified collagen made of a natural collagen-containing material. The barrier laminate contains a barrier layer comprising a smooth barrier surface and a fibrous surface on the side opposite the above smooth surface. Additionally, the matrix layer comprises the collagen sponge material made of pig skin. The presented multilayer structure is adapted so that the matrix layer is absorbed by the body within approximately 2-5 weeks, while the collagen barrier laminate is absorbed substantially completely within approximately 6-11 weeks.

EFFECT: group of inventions provides the effective skin replacement for the purpose of skin reconstruction, repair and regeneration, eg following surgical interventions.

35 cl, 3 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: invention represents an agent for accelerating wound healing and tissue regeneration, containing oxymethyluracil, loratadine, sodium alginate, glycerol, a stabilising agent, a preserving agent and distilled water; the ingredients of the agent are taken in certain proportions, wt %.

EFFECT: accelerating wound healing and tissue regeneration, as well as possesses the pronounced immunomodulatory, anti-inflammatory, anti-allergic, anti-pruritic, anti-edematous and wound-healing action.

2 cl, 3 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to chemistry and presents a conjugation product, comprising polysaccharides T1 and T2, where the monosaccharides which form the polysaccharides T1 and T2 are bonded to each other by alpha-1,4-glycosidic links. At least one of the polysaccharides T1 and/or T2 comprises at least one amino group. T1 and T2 are bonded to each other covalently by a linker. T1 and/or T2 carry m groups -(L-A), wherein A is glucosaminoglycan or a derivative of glucosaminoglycan, glucosaminoglycan or a derivative of glucosaminoglycan with fluorescence labels, L is a second linker, by which T1 and/or T2 are covalently bonded to A, and m is at least 1.

EFFECT: invention also relates to a pharmaceutical composition, comprising a bonded product; use of the product in medicine and cosmetology and to the method of preparation of the bonded product.

22 cl, 5 ex

FIELD: medicine.

SUBSTANCE: invention represents an anti-inflammatory antibacterial wound-healing agent containing a polyethylene oxide base with molecular weight 400 (PEO-400) as a forming agent, as well as polyethylene oxide with molecular weight 1,500 (PEO-1500); an active substance is chloramphenicol and methyluracil; the agent is characterised by the fact that it additionally contains rifampicin and/or cycloserine; the cycloserine content in the rifampicin mixture is specified within the range of 18 to 82 wt %, whereas the ingredients are taken in certain ratio, wt %.

EFFECT: invention provides more effective healing of open wounds, ulcers, bedsores, as well as increased necrolytic effect, reduced exudation, and also a lower risk of allergic reactions.

3 cl, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and concerns a method for making an activated leukocyte composition involving human leukocyte incubation, exposure to hypotonic shock and addition of physiologically acceptable saline in an amount sufficient for the reconstitution of isotonicity, to the leukocytes. The group of inventions also concerns using: the activated leukocyte composition in preparing a drug for wound healing; a wound healing dressing containing the above composition.

EFFECT: group of inventions provides preparing the composition containing a 90 times increase of the leukocyte count as compared to the known state-of-the-art methods.

16 cl, 3 dwg, 6 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology, and can be used for the treatment of local skin I-II degree radioreactions on irradiation fields after neutron therapy in patients with head and neck malignancies. For this purpose the applications of ozonised sunflower oil with peroxide number 18% and acid number 71 mg KON/g are performed on the area of the affected skin. The impact is performed after a session of neutron therapy 1-2 times per day for 4-5 days.

EFFECT: method ensures the reduction of the number of radioreactions and skin injuries due to optimally selected parameters of the applied medication, capable of the fast arrest of pain syndrome, reduction of oedema of surrounding tissues, wound-healing action in specific irradiation conditions.

4 dwg, 1 ex

Haemostatic agent // 2545991

FIELD: medicine.

SUBSTANCE: invention relates to medicine and veterinary and is intended for the acceleration of stopping bleeding in case of injury to blood vessels in traumas and wounds. A haemostatic agent contains 3-20 wt % of a polysaccharide, where the polysaccharide is represented by chitosan and/or starch, 0.1-2 wt % of calcium chloride and a 0.5-5% water solution of succinic or hydrochloric acid - the remaining part.

EFFECT: accelerating the initiation of the thrombus-forming process and enhancement of the regenerative ability of tissues in the area of wounds of different aetiology.

1 tbl, 14 ex

FIELD: medicine.

SUBSTANCE: method for preparing a gel for wound and burn healing involving diluting chitosan in an organic acid, combining it with a biologically active substance and water; chitosan is diluted in citric or lactic acid; mussel hydrolysate is used as the biologically active substance; the hydrolysate is added to the chitosan solution before PEG 600 and calcium alhylose are added in the certain environment.

EFFECT: method enables preparing the new effective wound-healing agent.

2 dwg, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical composition contains drug substances and a consistency-forming base. According to the invention, it contains anaesthetics as drug substances specified in a group: anaesthesine, lidocaine, promedol and antiseptic specified in a group of: ethacridine lactate, Furacilin, dioxidine, chlorhexidine, boric acid, 0.5% silver solution in the following ratio, g in 1 ml of the mixture: anaesthetics 0.00001-0.5; antiseptics 0.00001-0.5; consistency-forming base - the rest. Besides, it contains lysozyme in an amount of 0.1-0.3 g per 1 ml of the mixture, alpha-lipoic acid as an antioxidant in an amount of 0.00001-0.5 g per 1 ml of the mixture, regenerants specified in a group of: pantothenic acid, calcium pantotenate, beta-carotene, coenzyme Q, sodium deoxyribonucleate, inosine, vitamins A, D, E, K in an amount of 0.00001-0.5 g per 1 ml of the mixture, anabolics specified in a group of: methyluracil, riboxinum, potassium orotate, orotic acid, L-carnitine in an amount of 0.00001-0.5 g per 1 ml of the mixture, glycyrrhizic acid and/or its salts in an amount of 0.00001-0.5 g per 1 ml of the mixture, recombinant interferon specified in a group of: recombinant interferon-alpha, recombinant interferon-beta, recombinant interferon-gamma in an amount of 100-1,000,000 International units, glucocorticoids specified in a group of: hydrocortisone, prenisolone, polcortolone in an amount of 0.00001-0.5 g per 1 ml of the mixture. The consistency-forming base contains the components specified in a group: hypromellose, sodium alginate, acetyl phthalyl cellulose, macrogol, polyvinylpyrrolidone.

EFFECT: improving the properties of the composition.

9 cl, 11 ex

FIELD: medicine.

SUBSTANCE: what is described is a bioactive wound coating of a hydrogel nanocomposite, which contains antimicrobial and antioxidant ingredients: silver-modified montmorillonite and fullerenol used to optimise the clinical course of the wound process, to prevent and suppress a wound infection. The wound coating can be used to treat gun-shot injuries, severe mechanical injuries, infected and uninfected wounds, including septic and persistent, granulating wounds following deep thermal, chemical and radioactive burns, in the combined therapy of trophic ulcers and bed sores at hospital, in the outpatient setting and in the field. The wound coating is elastic, not fragmented in dressing that facilitates wound care. A high sorption ability of the wound coating matrix, including of coarse-molecular ingredients of the wound effluent, provides the fast elimination of the wound bed. Using the hydrogel, i.e. possessing high degree of hydration, the wound coating meets the modern wound management in the humid medium.

EFFECT: optimum conditions for the early activation of the repair processes.

5 dwg, 2 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to prodrug preparations of glucagon superfamily peptides, in which the glucagon superfamily peptide is modified by binding a dipeptide with the peptide of the glucagon superfamily by an amide bond.

EFFECT: produgs, disclosed in the claimed invention, have an increased half-life and transfer into an active form in physiological conditions as a result of a non-enzymatic reaction, caused by chemical instability.

30 cl, 15 dwg, 8 tbl, 16 ex

FIELD: medicine.

SUBSTANCE: invention represents an agent for accelerating wound healing and tissue regeneration, containing oxymethyluracil, loratadine, sodium alginate, glycerol, a stabilising agent, a preserving agent and distilled water; the ingredients of the agent are taken in certain proportions, wt %.

EFFECT: accelerating wound healing and tissue regeneration, as well as possesses the pronounced immunomodulatory, anti-inflammatory, anti-allergic, anti-pruritic, anti-edematous and wound-healing action.

2 cl, 3 ex, 1 tbl

FIELD: biotechnology.

SUBSTANCE: invention relates to a biodegradable synthetic polymer, namely to the polymer of the general formula (I) , where NA has the structure: , AN has the structure: , where n is an integer >2; Z is either absent or is an amino acid residue -NH-(CH2)i-CO-, where i - is an integer from 1 to 5; D represents a linear or branched alkyl C1-C5 or benzyl; B represents a residue of aliphatic diamine -NH-(CH2)k-NH-, where k is an integer from 2 to 6; X and Y can simultaneously have the following meanings: X=H-B, Y=H, or X=Nα-(D-OCO)-L-arginyl-Z-B, Y=Nα-(D-OCO)-L-arginyl-Z, or X=R1-AN-B, Y=NA-R1, where R1 is carboxamide-alkyl of the type H2NCO-CH2- or H2NCO-CH2CH2-. Such a polymer is capable of delivering the natural L-arginine into the tissues of human, animals, through biological membranes and can be used alone or in a combination with other active compounds.

EFFECT: invention enables to obtain the polymer soluble in water, which has no cytotoxicity and enhances the level of nitrogen oxide in the tissues of humans and animals.

2 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology, more specifically to a method for producing a mixture of mono- and di-pegylated IL-10, and can be used in medicine. The above method consists in carrying out a reaction of IL-10 protein in the concentration of 1 to 12 mg/ml with activated PEG-linker, wherein the relation of IL-10 and PEG-linker makes 1:1 to 1:7.7 in the presence of 25 to 35 mM of the reducing agent. The appropriate cases may require purifying the produced mixture of IL-10. The invention also refers to a pharmaceutical composition for treating a proliferative condition or disorder, containing a therapeutically effective amount of the mixture of mono- and di-pegylated IL-10 produced as described above, and a pharmaceutically acceptable carrier.

EFFECT: invention enables producing the mixture of mono- and di-pegylated IL-10 accompanied by no side products produced and keeping the protein dimer structure non-destructive.

16 cl, 2 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biochemistry, particularly to a recovered monoclonal anti-LOXL2 antibody or its antigen-binding fragment, as well as conjugates containing them. What is disclosed is a pharmaceutical composition for treating a disease related to angiogenesis, fibrosis, tumour or metastases, containing the above recovered monoclonal anti-LOXL2 antibody or its antigen-binding fragment in an effective amount. The invention also refers to a method for determining and/or measuring LOXL2 in a biological sample, to a method for inhibiting LOXL2 activity, to a method for reducing growth of LOXL2-expressing tumour in an individual in need thereof, to a method for inhibiting angiogenesis in the individual in need thereof, to a method for suppressing a fibrous disease in the individual in need thereof, as well as to a method for monitoring an individual's response to an anti-LOXL2 therapy with using the above antibody or its antigen-binding fragment and the above conjugate.

EFFECT: invention enables treating the LOXL2-related diseases effectively.

28 cl, 6 dwg, 6 tbl, 9 ex

FIELD: chemistry.

SUBSTANCE: invention relates to chemistry and presents a conjugation product, comprising polysaccharides T1 and T2, where the monosaccharides which form the polysaccharides T1 and T2 are bonded to each other by alpha-1,4-glycosidic links. At least one of the polysaccharides T1 and/or T2 comprises at least one amino group. T1 and T2 are bonded to each other covalently by a linker. T1 and/or T2 carry m groups -(L-A), wherein A is glucosaminoglycan or a derivative of glucosaminoglycan, glucosaminoglycan or a derivative of glucosaminoglycan with fluorescence labels, L is a second linker, by which T1 and/or T2 are covalently bonded to A, and m is at least 1.

EFFECT: invention also relates to a pharmaceutical composition, comprising a bonded product; use of the product in medicine and cosmetology and to the method of preparation of the bonded product.

22 cl, 5 ex

FIELD: medicine.

SUBSTANCE: invention represents a balanced infusion solution containing sodium, potassium and magnesium chlorides, a solvent and sodium L-arginine succinate of formula: Na+[NH=C(NH2)NH(CH2)3CH(NH2)COOH]+[OOC(CH2)2COO]2-. The ingredients in the solution are found in certain proportions, wt %.

EFFECT: invention provides enhanced detoxification activity, low toxicity and wide range of clinical applications.

11 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry and represents a formulation specially adapted for insulin transformation into the aerosol state, containing insulin in water from 100 IU/ml to 1,200 IU/ml and 2 to 4 Zn2+ ions per the insulin hexamer, wherein the formulation is preservative-free and wherein the formulation is able to transform into the aerosol state as an aerosol spray when using a holed vibration plate with no foaming of the formulation, when the formulation is kept on a back surface of the holed plate by gravity, and the spray is ejected from the front surface of the holed plate entirely by vibrating the holed plate.

EFFECT: invention provides reducing the foaming of the formulation, the time of transformation into the aerosol state and providing the more effective administration of an insulin dose.

19 cl, 5 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds providing the targeted drug delivery to CD1d receptor cells and inducing an immune response as compared to an antigen, to based compositions and to a method using them applicable in medicine, of formula

,

wherein R1, R2, R3, and R4 represents hydrogen; R6 represents -(CH2)xCH3, x represents an integer from 20 to 25, or -(CH2)xCH=CH(CH2)yCH3, x, y and z independently represent an integer from 1 to 14, R5 is described by formula

,

wherein R8 represents hydrogen, R7 represents C3-C15 alkyl; X represents N; X represents -(CH2)t, wherein t is an integer within 3-10; Z represents a peptide antigen.

EFFECT: prepared are the new biologically active compounds effective for simulating the immune response.

12 cl, 6 dwg, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, more specifically to pharmacology, and concerts agents having an effect on the rheological properties of blood. What is presented is using the chemical modification product of hydroxyethylated starch O-(2-hydroxyethyl)-(1,4)-α-D-glucan, the hybrid macromolecular compound O-(4-hydroxy-3,5-di(1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)benzyl)oxy)ethyl)-O-(2-hydroxyethyl)-(1,4)-α-D-glucan as an agent improving the rheological properties of blood. The invention can be used in a complex therapy of pathologies accompanied by blood hyperviscosity.

EFFECT: limiting an increase in blood viscosity.

4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and can be used for treating a human patient suffering acid lysosome lipase (ALL) deficiency. That is ensured by administering human recombinant ALL into the above human patient in an amount effective to normalise hepatic transaminase in serum or blood. The above human recombinant ALL is administered once approximately every 7 days to once approximately every 30 days, and the above dose is adequate to reducing the hepatic involvement in the above human patient.

EFFECT: invention provides treating the ALL deficiency, such as Wolman disease, cholesterol ester storage disease (CESD) both at the early, and late stages of the disease.

32 cl, 19 dwg, 12 tbl, 18 ex

Up!